MethylGene Launches Trial for Cancer Drug Combination
MethylGene has initiated a Phase II clinical trial evaluating MGCD0103 in combination with injections of Vidaza for patients with high-risk myelodysplastic syndromes or acute myeloid leukemia.
MGCD0103 is an orally-administered, isoform-selective inhibitor. The three-arm, randomized trial will compare the drug combination with monotherapy in 180 patients at cancer centers in North America and Europe, the company said.
MGCD0103 has received orphan drug designation from the FDA.